Paeoniflorin Attenuates Myocardial Fibrosis in Isoprenaline-induced Chronic Heart Failure Rats via Inhibiting P38 MAPK Pathway

Abstract

Paeoniforin (Pae) is a monoterpenoid glycoside compound and has many biological activities, such as immunosuppression, anti-inflammation and anti-cell proliferation. However, the effects and mechanisms of Pae on chronic heart failure (CHF) remain unclear. This study was conducted to assess the effects and mechanisms of Pae on myocardial fbrosis in isoprenaline (Iso)-induced CHF rats. Pae (20 mg/kg) was intragastrically administrated to CHF rats for 6 weeks. Cardiac structure and function were assessed. The protein and mRNA levels of transforming growth factor β1 (TGF-β1) and p38 were detected. Compared to Iso group, Pae could alleviate myocardial fibrosis and improve cardiac function in CHF rats. The levels of collagen volume fraction (13.75%±3.77% vs. 30.97%±4.22%, P<0.001) and perivascular collagen volume area (14.32%±2.50% vs. 28.31%±3.16%, P<0.001) were signifcantly reduced in Pae group as compared with those in Iso group. The expression of TGF-β1 protein (0.30±0.07 vs. 0.66±0.07, P<0.05) and mRNA (3.51±0.44 vs. 7.58±0.58, P<0.05) decreased signifcantly in Pae group as compared with that in Iso group. The expression of p38 protein (0.36±0.12 vs. 0.81±0.38, P<0.05) and mRNA (3.84±0.05 vs. 4.40±0.17, P<0.05) also decreased markedly in Pae group as compared with that in Iso group. Pae could attenuate myocardial fbrosis and improve cardiac function in CHF rats by down-regulating the p38 MAPK signaling pathway.

Keywords

chronic heart failure / paeoniflorin / myocardial fibrosis / p38 / transforming growth factor β1

References

[1] PonikowskiP, VoorsAA, AnkerSD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2016, 18(8): 891-975

[2] KongP, ChristiaP, FrangogiannisNG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci, 2014, 71(4): 549-574

[3] LiuM, ChenJ, HuangY, et al.. Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-beta1/Smad3 and p38 MAPK signaling pathway. Pharmazie, 2016, 2015(70): 4-244

[4] JiY, WangT, WeiZF, et al.. Paeoniflorin, the main active constituent of Paeonia lactiflora roots, attenuates bleomycin-induced pulmonary fibrosis in mice by suppressing the synthesis of type I collagen. J Ethnopharmacol, 2016, 2013(149): 3-825

[5] ChenH, DongY, HeX, et al.. Paeoniflorin improves cardiac function and decreases adverse postinfarction left ventricular remodeling in a rat model of acute myocardial infarction. Drug Des Devel Ther, 2018, 12: 823-836

[6] ShaoYX, XuXX, WangK, et al.. Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway. Drug Des Devel Ther, 2017, 11: 3221-3233

[7] JiY, DouYN, ZhaoQW, et al.. Paeoniflorin suppresses TGF-beta mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway. Acta Pharmacol Sin, 2016, 2016(37): 6-794

[8] LiuM, ChenJ, YaoJ, et al.. Triptolide Attenuates Cardiac Remodeling in Isoprenaline-induced Chronic Heart Failure Rats via Upregulating PTEN Pathway. J Sun Yat-sen Univ Med Sci (Chinese), 2017, 1: 29-35

[9] PrabhuSD, FrangogiannisNG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res, 2016, 2016(119): 1-91

[10] ZhangY, BauersachsJ, LangerHF. Immune mechanisms in heart failure. Eur J Heart Fail, 2016, 2017(19): 11-1379

[11] LiH, JiaoY, XieM. Paeoniflorin Ameliorates Atherosclerosis by Suppressing TLR4-Mediated NF-kappaB Activation. Inflammation, 2016, 2017(40): 6-2042

[12] WangZ, LiuZ, YuG, et al.. Paeoniflorin Inhibits Migration and Invasion of Human Glioblastoma Cells via Suppression Transforming Growth Factor beta-Induced Epithelial-Mesenchymal Transition. Neurochem Res, 2016, 2018(43): 3-760

[13] ZhaoY, MaX, WangJ, et al.. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1alpha through mTOR-dependent pathway. Fitoterapia, 2014, 99: 318-327

[14] ZhouH, YangHX, YuanY, et al.. Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFbeta/Smads and NF-kappaB pathways. J Mol Histol, 2016, 2013(44): 3-357

[15] LiuX, ChenK, ZhuangY, et al.. Paeoniflorin improves pressure overload-induced cardiac remodeling by modulating the MAPK signaling pathway in spontaneously hypertensive rats. Biomed Pharmacother, 2019, 111: 695-704

[16] YokotaT, WangY. p38 MAP kinases in the heart. Gene, 2016, 575(2Pt2): 369-376

[17] WangP, WangW, ShiQ, et al.. Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitisinduced acute renal injury. Mol Med Rep, 2016, 2016(14): 2-1123

[18] FangC, MaC, JiangL, et al.. p38 MAPK is crucial for Wnt1- and LiCl-induced epithelial mesenchymal transition. Curr Med Sci, 2018, 38(3): 473-481